Ebola Virus DiseaseNCT03576690
R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease
A study testing REGN3470-3471-3479 in people with Ebola Virus Disease, run by Regeneron Pharmaceuticals.
Trial summary
Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Ebola Virus Disease
- What is being tested?
- REGN3470-3471-3479
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Start not givento not given
- Phase
- Expanded access
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Who may be able to join
- Males or females in an Ebola endemic region with documented positive polymerase chain reaction (PCR) for Ebola virus infection who are symptomatic
- Ability to provide informed consent personally or by a legal representative if the patient is unable to do so, based on local laws and regulations
- REGN-EB3 can be administered to pregnant women infected with Zaire ebolavirus, as defined in the protocol
- Children of any age will be eligible for enrollment, as defined in the protocol
- Neonates born to an infected mother who has not yet cleared the Ebola virus are eligible for enrollment, as defined in the protocol
Who cannot join
- Negative EBOV diagnostic test result
- A patient who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol
- Any serious medical condition that, in the opinion of the site investigator, would place the patient at an unreasonable increased risk through participation in this study, including any past or concurrent conditions
- Eligible for an ongoing randomized clinical trial with REGN-EB3
- NOTE: Other protocol defined inclusion / exclusion criteria apply
Trial locations and contacts
No sites are listed yet.
Requests for compassionate use must be initiated by a treating physician. Physicians should contact contact
About this study
Official title: Expanded Access Protocol for Emergency Use of REGN3470-3471-3479 for the Treatment of Ebola Virus Disease
Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD).
- Conditions
- Ebola Virus Disease
- Being tested
- REGN3470-3471-3479
- Keywords
- Positive Ebola Virus (EBOV) diagnostic test, symptomatic
- Medical subject headings
- Hemorrhagic Fever, Ebola
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
REGN3470-3471-3479Biological
Also called REGN-EB3, Inmazeb®, atoltivimab, maftivimab, and odesivimab
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jul 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ebola Virus DiseaseStudies of the same condition, open and under way.
- More trials run by Regeneron PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- Regeneron Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03576690
- Sponsor's protocol ID
- R3470-3471-3479-EBOV-1846
- Status last verified
- Oct 2026
- First submitted
- 22 Jun 2018
- Last updated
- 9 Oct 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Expanded Access Protocol for Emergency Use of REGN3470-3471-3479 for the Treatment of Ebola Virus Disease
- ClinicalTrials.gov ID
- NCT03576690
- Acronym / sponsor ID
- R3470-3471-3479-EBOV-1846
- Conditions
- Ebola Virus Disease
- Keywords
- Positive Ebola Virus (EBOV) diagnostic test, symptomatic
- Study type
- Expanded access
- Recruitment status
- Available
- Lead sponsor
- Regeneron PharmaceuticalsIndustry (pharma, biotech, devices)
- First posted
- 3 Jul 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD).
Study design
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- Males or females in an Ebola endemic region with documented positive polymerase chain reaction (PCR) for Ebola virus infection who are symptomatic
- Ability to provide informed consent personally or by a legal representative if the patient is unable to do so, based on local laws and regulations
- REGN-EB3 can be administered to pregnant women infected with Zaire ebolavirus, as defined in the protocol
- Children of any age will be eligible for enrollment, as defined in the protocol
- Neonates born to an infected mother who has not yet cleared the Ebola virus are eligible for enrollment, as defined in the protocol
Key exclusion criteria (5 listed)
- Negative EBOV diagnostic test result
- A patient who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol
- Any serious medical condition that, in the opinion of the site investigator, would place the patient at an unreasonable increased risk through participation in this study, including any past or concurrent conditions
- Eligible for an ongoing randomized clinical trial with REGN-EB3
- NOTE: Other protocol defined inclusion / exclusion criteria apply
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| REGN3470-3471-3479Also: REGN-EB3, Inmazeb®, atoltivimab, maftivimab, and odesivimab | Biological | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2026.
Related trials for Ebola Virus Disease
Not yet recruitingPhase 2/3
Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo
Ebola Hemorrhagic Fever, Bundibugyo Virus Disease
Active, not recruitingPhase 1
A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants
Ebola-Bundibugyo Virus Disease (Ebola-BDBV)
RecruitingPhase 1
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health
Sudan Virus Disease
Active, not recruitingPhase 4
REVIVE (Response to the Ebola Virus Vaccine)
Ebola Virus Disease
Active, not recruitingPhase 2
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
Ebola Sudan Virus Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Requests for compassionate use must be initiated by a treating physician. Physicians should contact contact
Questions about this trial
What is this clinical trial studying?
A study testing REGN3470-3471-3479 in people with Ebola Virus Disease, run by Regeneron Pharmaceuticals.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Requests for compassionate use must be initiated by a treating physician. Physicians should contact (844-734-6643, compassionateuserequests@regeneron.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026; AzTrials last refreshed its copy on 26 Oct 2026.